NPM1 and acute myeloid leukemia: As shown in Table 1, in the six CN-AML patients from the microarray, three were diagnosed as better-risk AML, while the other three were diagnosed as poor-risk AML, based on whether they had FLT3-ITD and NPM1 mutation or not.